Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study

Asher A Chanan Khan, Jonathan L. Kaufman, Jayesh Mehta, Paul G. Richardson, Kena C. Miller, Sagar Lonial, Nikhil C. Munshi, Robert Schlossman, Joseph Tariman, Seema Singhal

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.

Original languageEnglish (US)
Pages (from-to)2604-2606
Number of pages3
JournalBlood
Volume109
Issue number6
DOIs
StatePublished - Mar 15 2007
Externally publishedYes

Fingerprint

Multiple Myeloma
Multicenter Studies
Renal Insufficiency
Dialysis
Retrospective Studies
Safety
Proteasome Inhibitors
Bortezomib
Therapeutics
Toxicity
Kidney
Population

ASJC Scopus subject areas

  • Hematology

Cite this

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure : A multicenter retrospective study. / Chanan Khan, Asher A; Kaufman, Jonathan L.; Mehta, Jayesh; Richardson, Paul G.; Miller, Kena C.; Lonial, Sagar; Munshi, Nikhil C.; Schlossman, Robert; Tariman, Joseph; Singhal, Seema.

In: Blood, Vol. 109, No. 6, 15.03.2007, p. 2604-2606.

Research output: Contribution to journalArticle

Chanan Khan, AA, Kaufman, JL, Mehta, J, Richardson, PG, Miller, KC, Lonial, S, Munshi, NC, Schlossman, R, Tariman, J & Singhal, S 2007, 'Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study', Blood, vol. 109, no. 6, pp. 2604-2606. https://doi.org/10.1182/blood-2006-09-046409
Chanan Khan, Asher A ; Kaufman, Jonathan L. ; Mehta, Jayesh ; Richardson, Paul G. ; Miller, Kena C. ; Lonial, Sagar ; Munshi, Nikhil C. ; Schlossman, Robert ; Tariman, Joseph ; Singhal, Seema. / Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure : A multicenter retrospective study. In: Blood. 2007 ; Vol. 109, No. 6. pp. 2604-2606.
@article{2611fe7a1a5b4b29a32b0b64fd547b8e,
title = "Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study",
abstract = "Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75{\%}, with 30{\%} CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.",
author = "{Chanan Khan}, {Asher A} and Kaufman, {Jonathan L.} and Jayesh Mehta and Richardson, {Paul G.} and Miller, {Kena C.} and Sagar Lonial and Munshi, {Nikhil C.} and Robert Schlossman and Joseph Tariman and Seema Singhal",
year = "2007",
month = "3",
day = "15",
doi = "10.1182/blood-2006-09-046409",
language = "English (US)",
volume = "109",
pages = "2604--2606",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure

T2 - A multicenter retrospective study

AU - Chanan Khan, Asher A

AU - Kaufman, Jonathan L.

AU - Mehta, Jayesh

AU - Richardson, Paul G.

AU - Miller, Kena C.

AU - Lonial, Sagar

AU - Munshi, Nikhil C.

AU - Schlossman, Robert

AU - Tariman, Joseph

AU - Singhal, Seema

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.

AB - Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=33947201310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947201310&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-09-046409

DO - 10.1182/blood-2006-09-046409

M3 - Article

C2 - 17138816

AN - SCOPUS:33947201310

VL - 109

SP - 2604

EP - 2606

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -